Tautz Lutz, Mustelin Tomas
Burnham Institute for Medical Research, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA.
Methods. 2007 Jul;42(3):250-60. doi: 10.1016/j.ymeth.2007.02.014.
Protein tyrosine phosphatases (PTPs) play vital roles in numerous cellular processes and are implicated in a growing number of human diseases, ranging from cancer to cardiovascular, immunological, infectious, neurological, and metabolic diseases. Here we present methods for developing small molecule inhibitors for these enzymes, starting with how to set up a high throughput chemical library screening for PTP inhibitors, how to confirm and prioritize hits, and how to circumnavigate possible pitfalls. Next, we present the relatively new hit generating method of in silico or virtual screening. We give an overview of existing software tools, describe how to choose and generate protein target structures and illustrate the procedure with examples. We then discuss how three-dimensional PTP structures can be analyzed in terms of their potential to bind small molecule inhibitors selectively over homologous proteins and how computer tools can be applied for lead optimization efforts. We finish with a perspective of how well these PTP inhibitors might perform as future drugs to treat human disease.
蛋白质酪氨酸磷酸酶(PTPs)在众多细胞过程中发挥着至关重要的作用,并且与越来越多的人类疾病相关,从癌症到心血管疾病、免疫疾病、感染性疾病、神经疾病和代谢疾病。在此,我们介绍开发这些酶的小分子抑制剂的方法,首先是如何建立针对PTP抑制剂的高通量化学文库筛选,如何确认命中化合物并对其进行优先级排序,以及如何规避可能的陷阱。接下来,我们介绍相对较新的基于计算机模拟或虚拟筛选的命中化合物生成方法。我们概述了现有的软件工具,描述了如何选择和生成蛋白质靶标结构,并举例说明操作过程。然后,我们讨论如何根据三维PTP结构相对于同源蛋白质选择性结合小分子抑制剂的潜力进行分析,以及如何将计算机工具应用于先导化合物优化工作。最后,我们展望了这些PTP抑制剂作为未来治疗人类疾病的药物可能的表现。